Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2004, for Phase III Medical, Inc. (formerly Corniche Group Incorporated). The company operates in two segments: the "run off" of its former internet-based extended warranty business and a new venture providing capital and guidance to medical/biotech companies in exchange for royalty interests. Management has raised substantial doubt about the company's ability to continue as a going concern due to limited financial resources and lack of current operations.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2004 | Six Months Ended June 30, 2003 |
|---|---|---|
| Revenue | $34,415 | $35,009 |
| Gross Profit | $10,271 | $9,909 |
| Operating Loss | $(794,340) | $(328,159) |
| Net Loss | $(948,386) | $(390,566) |
| Cash and Equivalents (End of Period) | $1,750 | $27,452 |
| Total Current Liabilities | $1,220,206 | $1,022,720 |
| Notes Payable | $540,000 | $400,000 |
| Preferred Dividends Payable | $457,037 | $433,196 |
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased slightly to $34,415 from $35,009, derived entirely from the amortization of deferred revenues from prior warranty contracts.
- Significant Loss Increase: Net loss more than doubled to $948,386 from $390,566. This was primarily driven by a $480,000 charge for the purchase of a medical royalty stream from Parallel Solutions, Inc. (PSI), which was expensed immediately due to revenue uncertainty.
- Liquidity Deterioration: Cash and cash equivalents plummeted from $210,947 at year-end 2003 to just $1,750 at June 30, 2004. Net cash used in operating activities was $765,146.
- Debt and Defaults: The company is in default on multiple promissory notes totaling approximately $515,000 (including $125,000 from 2002, $250,000 from 2003, and $140,000 from 2004). Default penalties allow noteholders to purchase common stock at nominal prices.
Outlook, Risks, and Management Commentary
- Going Concern Warning: The filing explicitly states that the company has no current operations and limited resources to pay liabilities, raising substantial doubt about its ability to continue as a going concern.
- Capital Strategy: The company is relying on the sale of common stock (amended private placement up to $4 million) and high-interest promissory notes (up to 20%) to fund operations and fulfill a remaining $440,000 commitment to PSI.
- Strategic Partnerships:
- Parallel Solutions, Inc. (PSI): Company paid $480,000 in the period for a royalty interest in bioshielding technology. Total paid to date is $560,000.
- NeoStem, Inc.: Entered a joint venture to introduce clients for adult stem cell banking services. No revenue or payments have been realized to date.
- Stock Issuance: Issued 4,550,000 shares of common stock for $425,000 net proceeds during the six-month period. Additionally, 750,000 shares were reserved for issuance to noteholders exercising default penalty options.
Investor Verification Checklist
- Cash Runway: Verify if the company can meet immediate obligations with only $1,750 in cash and $1.22 million in current liabilities.
- Debt Default Status: Confirm the extent of defaults on promissory notes and the potential dilution from noteholders exercising conversion options at $125 for 25,000 shares.
- Royalty Asset Viability: Assess the likelihood of the $480,000 investment in PSI generating future revenue, given the immediate expensing of the cost.
- Capital Raising Progress: Monitor the status of the amended private placement to determine if the company can raise the necessary funds to avoid insolvency.
- Preferred Stock Obligations: Review the $457,037 in accrued dividends on Series A Preferred Stock and the conditions for redemption.